Tango Therapeutics raises ~$566.5M in public offering to fund R&D and commercialization

Tango Therapeutics, Inc.

Offering of 18,166,667 shares at $30.00/share and pre-funded warrants for 1,833,395 shares at $29.999/warrant.
Net proceeds expected ~$566.5M after underwriting discounts and expenses; closing expected June 11, 2026.
Proceeds for R&D, pivotal trial, potential commercialization, G&A, and capex; cash runway extended into 2030.
Underwriters granted 30-day option to purchase up to 3,000,009 additional shares at public offering price.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tango Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives (effective 2026-06-09).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC and Leerink Partners LLC as representatives
Effective: 2026-06-09

Exact text from the filing

On June 9, 2026, Tango Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives (the “Representatives”) to the several underwriters named in the Underwriting Agreement (collectively, the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 18,166,667 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,833,395 shares of Common Stock

View on SEC.gov

801 material agreements filed in the last 30 days. Browse all material agreements →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-266078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.